Statin therapy increases measures of asthma control in hyperlipidemic subjects with asthma, according to researchers at Kaiser Permanente Medical Group and other institutions in San Diego, California.
From a total of 117,922 asthmatic patients >18 years of age in their database, researchers identified 51,123 with a comorbid diagnosis of hyperlipidemia. They performed a case control analysis using cases defined by short-acting beta agonist canister dispensing >6 (SABA> 6), history of emergency department visits or hospitalizations (EDHO), or corticosteroid dispensing (CCS).
Hyperlipidemic asthmatic subjects were categorized by prescriptions for statins or non-statins. Diabetes mellitus, hypertension, reflux, BMI, gender, and race/ethnicity were analyzed as covariates. The researchers used univariate (UV) and multivariate (MV) analyses to generate odds ratios (OR) and confidence intervals (CI) .
Following data analysis, the use of statins in hyperlipidemic persons with asthma was associated with an increased risk of SABA>6 (UV OR 1.34, MV OR 1.22); EDHO (UV OR 1.29, MV OR 1.03); and CSS (UV OR 1.20, MV OR 1.17).